KeasClinical Studies ApS: Financial statements 2022
CVR: 40794492
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
KeasClinical Studies ApS (CVR 40794492) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -23,277 and a net result of DKK -10,427 compared with DKK 112,829 the year before. Equity in the 2022 report amounted to DKK 303,189. The solvency ratio was 97.9%.
- Gross Profit
- DKK -23,277
- Profit/Loss
- DKK -10,427
- Equity
- DKK 303,189
- Total Assets
- DKK 309,758
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -23 t. | -10 t. | 303 t. | - |
| 2021 | - | 151 t. | 113 t. | 663 t. | 0 |
Official annual report
Keep an eye on KeasClinical Studies ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
KeasClinical Studies ApS has published its annual report for 2021. Gross profit came to DKK 150,954, and the net result was DKK 112,829.
About KeasClinical Studies ApS
KeasClinical Studies ApS is a Danish company of the type Anpartsselskab based in Aarhus C, founded in 2019. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company was previously named Blitz Technology ApS. The management consists of Lone Bliksted Gitz-Johansen. The company is owned by Mette Albinus Grønbæk and Blitz Holding ApS. The company has 1 employee (2020). In 2025, the company reported a gross profit of DKK -23,492 and a net result of DKK -14,372 compared with DKK -607 the year before. Equity in the 2025 report amounted to DKK 78,298.